Oxford, United Kingdom
Genomics is a pioneering TechBio company transforming health and healthcare through the power of genomics since its founding in 2014. Established by four renowned geneticists from the University of Oxford, including Professor Sir Peter Donnelly and Professor Gil McVean, the company is at the forefront of the genomic prevention movement, offering a cutting-edge approach to sustainable healthcare.
The company's proprietary algorithms and databases uniquely connect genomic variations to biological measurements and disease outcomes, delivering innovative insights for both population-level healthcare systems and individual clinical risk assessments. Genomics collaborates with leading biopharma companies like Novo Nordisk and Vertex, underscoring its influence and reputation in the industry.
Headquartered in the United Kingdom with offices and labs across the US, Genomics boasts a multi-disciplinary workforce of over 150 experts. Its latest funding round, a £35.00M Late VC investment received on 01 January 2024, saw participation from F-Prime Capital, Foresite Capital, and Infinity Investment Partners, positioning it strongly for future growth in the Biopharma and Life Sciences sectors.
